Table 3.
Assessments and instruments used
|
Outcomes |
Instrument |
T1 |
T2 |
T3 |
|---|---|---|---|---|
| Primary endpoint | ||||
| Components of MetS (5): |
|
X |
X |
X |
| Biomarkers- Glucose, HDL, triglycerides |
Analyzed in peripheral blood |
X |
X |
X |
| Blood pressure |
Pressure cuff under resting conditions |
X |
X |
X |
| Waist circumference |
Measuring tape |
X |
X |
X |
|
Secondary endpoints |
|
|
|
|
| Cardiorespiratory fitness |
4-minute walk test |
X |
X |
X |
| Muscle strength |
10-RM- leg extension, leg flexion, chest press, seated row |
X |
X |
X |
| Body composition |
DEXA, weight, height, lean mass, % body fat, hip circumference |
X |
X |
X |
| Quality of life |
SF-36, FACT-B, CES-D |
X |
X |
X |
| Shoulder strength |
Muscle force for SE and ER |
X |
X |
X |
| Shoulder ROM |
Measured with goniometer at 90° ER, forward flexion, |
X |
X |
X |
| Upper limb musculoskeletal disorder assessment |
DASH, PSS |
X |
X |
X |
| Biomarkers- inflammation & endocrine function |
Analyzed in peripheral blood |
X |
X |
X |
|
Others |
|
|
|
|
| Breast cancer characteristics |
Family history, TNM status, ER/PR status, HER-2 score |
X |
|
|
| Medical history |
Recording of any pre-existing disease and allergies |
X |
|
|
| Treatment data | Pre-treatment: date and type of breast cancer, affected lymph nodes, chemotherapy type and dose, radiation- technique, type, dose, start/stop date, hormone therapy | X |